Specific situations that may prevent continued therapy need to be monitored during the treatment: local cutaneous reactions, difficulty breathing and chest pain for GA, flu-like syndromes, cutaneous reactions, depression and hepatopathy for IFNβ, and hepatopathy, diarrhea, nausea and alopecia for teriflunomide. Here, IFNB1 is linked to depressive disorder.